• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Packaging Technology

    Elemental Impurities: The Time Has Come

    Continuous vs. Batch Production

    2018: The evolution of pharmaceutical packaging

    Formulation Development Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Sterling Pharma Invests £6M To Expand Offerings

    Bioclinica Announces Key Hires & Promotion

    PhoenixMD, STA Enter Manufacturing Agreement

    ProBioGen, Tizona Therapeutics Enter Collaboration

    Mayne Pharma Opens $80M Oral Solid Dose Facility
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Arcinova Receives £1.5M Innovate UK Grant

    Vetter Announces Visit from Illinois Governor

    Sterling Pharma Invests £6M To Expand Offerings

    PhoenixMD, STA Enter Manufacturing Agreement

    Mayne Pharma Opens $80M Oral Solid Dose Facility
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    INTERPHEX: Adents Showcases Cloud-Based Serialization Solution

    Almac Group Expands Packaging Capabilities

    Catalent Bolsters Clinical Supply Capabilities

    West, Stevanato Group Enter Ompi EZ-fill Alliance

    Pharmaceutical Packaging Technology
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Sterling Pharma Invests £6M To Expand Offerings

    PhoenixMD, STA Enter Manufacturing Agreement

    ProBioGen, Tizona Therapeutics Enter Collaboration

    INTERPHEX: Adents Showcases Cloud-Based Serialization Solution

    SAMDI Tech Enters Drug Discovery Collaboration
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Blockchain: The Next Big Trend in BioPharma?

    Emergent Completes Market Authorization

    Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle: ICH Q12

    LSNE Expands Capabilities and QC Laboratory Space

    Evotec Launches Drug Development Service
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    iuvo BioScience

    Almac Group

    Piramal Pharma Solutions

    Legacy Pharmaceutical Packaging

    Unither Pharmaceuticals
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    REGENX Licenses NAV Vectors to Voyager

    Gains non-exclusive license for the treatment of CNS disorders

    Related CONTENT
    • Onconova, SymBio Complete License Agreement
    • Galenea, Eisai in Neurodegenerative Disease Alliance
    • Grünenthal, Amura in Protease Pain Pact
    • Zenith Licenses Kinex Programs
    • Agilis, Intrexon in Rare Disease Pact
    06.02.14
    REGENX Biosciences, LLC and Voyager Therapeutics have entered into a license agreement for the use of REGENX's NAV vectors for the development and commercialization of gene therapies to treat Amyotrophic Lateral Sclerosis (ALS), Friedreich's ataxia (FA) and Huntington's disease (HD).
     
    Voyager has a non-exclusive worldwide license, as well as sublicensing rights, to the NAV vectors for the treatment of ALS, FA and HD. REGENX will receive an undisclosed upfront payment, ongoing fees, milestones, and royalties on sales of products incorporating NAV vectors. REGENX will also receive certain sublicensing revenues.
     
    "This license agreement serves as further validation of our proprietary NAV vector technology platform, and is an important step toward the successful development of NAV-based gene delivery treatments for patients afflicted with the serious and debilitating rare diseases to which Voyager is committed," said Ken Mills, president and chief executive officer of REGENX. "As the leader in next-generation AAV gene therapy, REGENX is pleased to be collaborating with Voyager, which is well-positioned to develop innovative treatments through the application of our NAV technology."
     
    Mark Levin, interim chief executive officer of Voyager, said, "Voyager is the leading
    AAV gene therapy company focused on developing life-changing treatments for patients with devastating CNS disorders. We are committed to advancing the AAV gene therapy field via broad-based investment in a number of key technological areas. In addition to providing a valuable addition to Voyager's intellectual property portfolio, the rights to use REGENX's NAV vectors will position us to rapidly advance the development of breakthrough CNS gene therapies."
    Related Searches
    • Methods Development
    • Development
    • Toxicology
    • Validation
    Suggested For You
    Akebia Therapeutics Names CMO  Akebia Therapeutics Names CMO
    Merck, Stelis Open First Joint Process Scale-Up Lab in Bengaluru Merck, Stelis Open First Joint Process Scale-Up Lab in Bengaluru
    MilliporeSigma Develops New CRISPR Genome Editing Method MilliporeSigma Develops New CRISPR Genome Editing Method
    LSNE, Selecta Biosciences Form Mfg. Pact LSNE, Selecta Biosciences Form Mfg. Pact
    Selexis SA and OSE Immunotherapeutics Enter Pact Selexis SA and OSE Immunotherapeutics Enter Pact
    Biogen to Spin Off Its Hemophilia Business Biogen to Spin Off Its Hemophilia Business
    RXi Pharma and Thera Neuropharma Enter License Agreement RXi Pharma and Thera Neuropharma Enter License Agreement
    Goodwin Biotechnology Completes cGMP Manufacturing of an IgM Monoclonal Antibody Goodwin Biotechnology Completes cGMP Manufacturing of an IgM Monoclonal Antibody
    Biogen, HudsonAlpha Identify Sporadic ALS Gene
 Biogen, HudsonAlpha Identify Sporadic ALS Gene
    Agilis, Intrexon in Rare Disease Pact Agilis, Intrexon in Rare Disease Pact
    Zenith Licenses Kinex Programs Zenith Licenses Kinex Programs
    Grünenthal, Amura in Protease Pain Pact Grünenthal, Amura in Protease Pain Pact
    Galenea, Eisai in Neurodegenerative Disease Alliance Galenea, Eisai in Neurodegenerative Disease Alliance
    Onconova, SymBio Complete License Agreement Onconova, SymBio Complete License Agreement

    Related Breaking News

    • Bio News | cGMP Manufacture | Clinical Trial Materials | Collaborations & Alliances | Industry News
      PhoenixMD, STA Enter Manufacturing Agreement

      PhoenixMD, STA Enter Manufacturing Agreement

      To manufacture the PMD-026 needed for IND-enabling toxicology studies and a Phase I study in women
      04.18.18

    • Bio News | Collaborations & Alliances | Industry News
      ProBioGen, Tizona Therapeutics Enter Collaboration

      ProBioGen, Tizona Therapeutics Enter Collaboration

      To develop immune system centered treatments for cancer
      04.18.18

    • Bio News | Collaborations & Alliances | Industry News
      Telix, INSERM, and ARRONAX Enter Agreement

      Telix, INSERM, and ARRONAX Enter Agreement

      To explore the feasibility of using several of Telix's clinical targeting agents with astatine
      04.16.18


    • Bio News | Breaking News | Collaborations & Alliances | Industry News
      Servier Acquires Shire Oncology Business for $2.4B

      Servier Acquires Shire Oncology Business for $2.4B

      The gross assets that are the subject of the transaction are approximately $1.6 billion
      04.16.18

    • Bio News | Collaborations & Alliances | Industry News
      Idera, Pillar Partners Enter Agreement

      Idera, Pillar Partners Enter Agreement

      Pillar Partners will provide funding to support three clinical trials to expand the clinical research of Idera's IMO-2125
      04.16.18

    • Bio News | Collaborations & Alliances | Industry News
      Kineta, Genentech Enter Collaboration

      Kineta, Genentech Enter Collaboration

      To develop Kineta's α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain
      04.16.18


    • Bio News | Collaborations & Alliances | Facilities | Industry News
      Sartorius Stedim Biotech, Penn State Enter Partnership

      Sartorius Stedim Biotech, Penn State Enter Partnership

      To support the education and preparation of the next generation of biotechnology leaders
      04.16.18

    • Bio News | Collaborations & Alliances | Industry News | Trials & Filings
      Argenx Achieves Preclinical Milestone

      Argenx Achieves Preclinical Milestone

      In its collaboration with LEO Pharma, for ARGX-112
      04.12.18

    • Industry News | Promotions & Moves
      Selexis Installs $2M in New Lab Equipment

      Selexis Installs $2M in New Lab Equipment

      The company also made key strategic hires and signed its one hundredth commercial license agreement (CLA)
      04.12.18


    • Bio News | Facilities | Industry News
      Sanofi Invests €350M in New Facility

      Sanofi Invests €350M in New Facility

      At the Sanofi Pasteur Canadian headquarters in Toronto, Ontario
      04.12.18

    • Bio News | Collaborations & Alliances | Industry News
      GSK, Orchard Therapeutics Enter Strategic Agreement

      GSK, Orchard Therapeutics Enter Strategic Agreement

      GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard
      04.12.18

    • Bio News | Breaking News | Industry News | Regulatory Affairs
      Emergent Completes Market Authorization

      Emergent Completes Market Authorization

      For BioThrax (Anthrax Vaccine Adsorbed) in five Concerned Member States (CMS) within the European Union (EU)
      04.12.18

    • Bio News | Collaborations & Alliances | Facilities | Industry News
      MilliporeSigma, Oxford University Enter Partnership

      MilliporeSigma, Oxford University Enter Partnership

      To develop a vaccine manufacturing facility in Ghana and to expand their scalable vaccine manufacturing processes
      04.12.18

    • Bio News | Breaking News | Industry News | Trials & Filings
      FDA Approves Novartis’ Afinitor

      FDA Approves Novartis’ Afinitor

      For the treatment of adult and pediatric patients with tuberous sclerosis complex with associated partial onset seizures
      04.11.18

    • Bio News | Collaborations & Alliances | Industry News
      Zealand, Roche Diabetes Care Enter Collaboration

      Zealand, Roche Diabetes Care Enter Collaboration

      For the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI)
      04.11.18

    Breaking News
    • Sterling Pharma Invests £6M To Expand Offerings
    • AGC Chemicals to Feature Advanced Intermediates
    • Avema to Showcase Range of Services
    • Peter Stein to Deliver FDA Keynote Presentation
    • CPhI NA Conference to Focus on Fostering Innovation
    View Breaking News >
    CURRENT ISSUE

    April 2018

    • Pharmaceutical Packaging Technology
    • Elemental Impurities: The Time Has Come
    • Continuous vs. Batch Production
    • 2018: The evolution of pharmaceutical packaging
    • Formulation Development Trends
    • Changing Dynamics: The CDMO market in focus
    • Contract BioManufacturing in China: Creating a New Segment
    • View More >

    Copyright © 2018 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.